China’s skyrocketing development of artificial intelligence (AI) will further enhance the country’s digital health industry, GlobalData announced. The new releases of recent AI models Qwen2.5-Max, Kimi k1.5, and DeepSeek v3 demonstrate China’s rising stakes in the arena of AI and its influence on medical products.
China represented about 20% of the Asia-Pacific (APAC) region’s digital health market in 2024, reflecting increasing demand for AI-based healthcare solutions. Some of the best AI applications in healthcare include better diagnostic ability, personalized treatment remedies, and enhanced physician-patient interaction.
Alibaba Cloud asserts that Qwen2.5-Max outperformed other AI models such as Llama-3.1-405B and DeepSeek V3, in various applications. As AI continues to evolve in China, additional improvements in post-training techniques may render the next iteration of Qwen2.5-Max all the better for medical AI applications.
Despite such advancements, there are still problematic areas. The main difficulties include – securing data privacy, upholding rigorous doctor-patient relationships, and the lack of trained AI talents.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.